FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA
A. Tedeschi,J. Burger,P.M. Barr,T. Robak,C. Owen,P. Ghia,O. Bairey,P. Hillmen,S. Coutre,S. Devereux,S. Grosicki,H. McCarthy,J. Li,D. Simpson,F. Offner,C. Moreno,S. Dai,I. Lal,J.P. Dean,T.J. Kipps
DOI: https://doi.org/10.1002/hon.67_2629
IF: 4.85
2019-01-01
Hematological Oncology
Abstract:Introduction: Ibrutinib (ibr) is a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase (BTK) approved in the EU and other regions to treat chronic lymphocytic leukemia (CLL). The phase 3 RESONATE-2 study compares the efficacy and safety of first-line ibr vs chlorambucil (chl) in older patients (pts) with CLL/small lymphocytic lymphoma (SLL). There is a critical clinical need for long-term efficacy and safety data for ibr, which is given as continuous therapy. Methods: RESONATE-2 is a phase 3, randomized, open-label, international study (PCYC-1115/1116; NCT01722487, NCT01724346). Pts with previously untreated CLL/SLL without 17p deletion and ≥65 y old (N=269) were randomized 1:1 to continuous ibr 420 mg once daily or chl 0.5–0.8 mg/kg for up to 12 cycles. Efficacy was assessed by investigator per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria with modification during long-term follow-up. Prevalence rates for adverse events (AE) are reported. Results: Baseline characteristics were well balanced between ibr and chl arms. After a median follow-up of 60 mo (range 0.1–66 mo), superior progression-free survival (PFS) was sustained for ibr vs chl (hazard ratio [HR] 0.15 [95% CI 0.10–0.22]). PFS estimates at 5 y were 70% for ibr vs 12% for chl. Ibr improved PFS compared to chl in pts with unmutated immunoglobulin heavy chain variable region (IGHV; HR 0.11 [95% CI 0.06–0.19]), 11q deletion (HR 0.03 [95% CI 0.01–0.11]), and the high-risk genomics subgroup (unmutated IGHV, 11q deletion, and/or TP53 mutation; HR 0.08 [95% CI 0.05–0.15]). Ibr also resulted in improved overall survival (OS) vs chl; 83% vs 68% at 5 y, even with 57% of pts crossing over from chl to ibr after progression. With ibr, overall response rate, including partial response with lymphocytosis, for ibr was 92%. The complete response (CR)/CR with incomplete marrow recovery (CRi) rate increased to 30% at 60 mo from 11% at primary analysis (18 mo). Common grade ≥3 AEs included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), hyponatremia (6%), atrial fibrillation (5%), and cataract (5%), with rates of most events decreasing over time. Dose reductions due to grade ≥3 AEs decreased over time and discontinuation rates due to AEs remained stable over time. After ibr discontinuation, pts responded to subsequent CLL therapies, such as chemoimmunotherapy and alternate kinase inhibitors. Ibr maintains benefit in 58% of pts who remained on therapy. Keywords: chronic lymphocytic leukemia (CLL); ibrutinib; small lymphocytic lymphoma (SLL). Disclosures: Tedeschi, A: Consultant Advisory Role: Janssen-Cilag, Gilead, AbbVie, Sunesis; Other Remuneration: Speakers bureau: Janssen. Burger, J: Consultant Advisory Role: Janssen; Honoraria: Janssen; Research Funding: Gilead, TG Therapeutics, Pharmacyclics LLC, an AbbVie Company, Beigene; Other Remuneration: Travel, Accommodations, Expenses: Gilead, TG Therapeutics, Pharmacyclics LLC, an AbbVie Company, Novartis, Janssen; Speakers Bureau: Gilead, TG Therapeutics, Pharmacyclics LLC, an AbbVie Company, Novartis, Janssen. Barr, P: Consultant Advisory Role: Pharmacyclics LLC, an AbbVie Company; Research Funding: Pharmacyclics LLC, an AbbVie Company. Robak, T: Research Funding: Pharmacyclics LLC, an AbbVie Company. Owen, C: Honoraria: Janssen, AbbVie, Roche, Merck, Teva, AstraZeneca; Research Funding: Celgene, AbbVie, Roche, Pharmacyclics LLC, an AbbVie Company, Gilead, AstraZeneca/Acerta, Novartis. Ghia, P: Consultant Advisory Role: AbbVie, Acerta, BeiGene, Gilead, Janssen, Roche, Sunesis; Honoraria: AbbVie, Acerta, BeiGene, Gilead, Janssen, Roche, Sunesis; Research Funding: AbbVie, Gilead, Janssen, Novartis; Other Remuneration: Speakers bureau: Gilead. Bairey, O: Consultant Advisory Role: AbbVie; Research Funding: Janssen. Hillmen, P: Consultant Advisory Role: Janssen, Pharmacyclics LLC, an AbbVie Company, AbbVie; Honoraria: Janssen, Pharmacyclics LLC, an AbbVie Company, AbbVie; Research Funding: Janssen, Pharmacyclics LLC, an AbbVie Company, AbbVie; Other Remuneration: Travel, Accommodations, Expenses: Janssen, AbbVie. Coutre, S: Consultant Advisory Role: BeiGene, AbbVie, Janssen; Honoraria: Pharmacyclics LLC, an AbbVie Company, Janssen; Research Funding: Gilead, Janssen, Pharmacyclics LLC, an AbbVie Company, AbbVie, Acerta. Devereux, S: Consultant Advisory Role: AbbVie, Janssen, GlaxoSmithKline, Bristol-Myers Squibb; Other Remuneration: Speakers bureau: Gilead, Janssen; Travel, Accommodations, Expenses: Janssen, Gilead. McCarthy, H: Consultant Advisory Role: Janssen; Honoraria: AbbVie, Janssen, Novartis, Roche; Other Remuneration: Travel, Accommodations, Expenses: AbbVie, Janssen, Novartis, Roche. Simpson, D: Honoraria: Celgene, Roche, MSD, Janssen; Research Funding: Amgen, MSD, Pharmacyclics LLC, an AbbVie Company, AbbVie, Sanofi, Roche, BeiGene, Acerta; Other Remuneration: Travel, Accommodations, Expenses: Celgene, Bristol-Myers Squibb, Novartis. Moreno, C: Consultant Advisory Role: Pharmacyclics LLC, an AbbVie Company, Janssen, AbbVie. Dai, S: Employment Leadership Position: Pharmacyclics LLC, an AbbVie Company; Stock Ownership: Pharmacyclics LLC, an AbbVie Company. Lal, I: Employment Leadership Position: Pharmacyclics LLC, an Abbvie Company, The Permanente Medical Group (TPMG); Stock Ownership: AbbVie, Gilead Sciences, Clovis, Infinity, TPMG, Reviva Pharmaceuticals. Dean, J: Employment Leadership Position: Pharmacyclics LLC, an AbbVie Company, CTI BioPharma Corp; Stock Ownership: Pharmacyclics LLC, an AbbVie Company, CTI BioPharma Corp. Kipps, T: Consultant Advisory Role: AbbVie, Genentech-Roche, Gilead, Pharmacyclics LLC, an AbbVie Company, Celgene; Research Funding: AbbVie, Genentech-Roche, Pharmacyclics LLC, an AbbVie Company, Oncternal.